Science Examines Vaccinemakers’ Ideas On How To Use CEPI Funding, Better Respond To Emerging Infections

Science: Epidemic Insurance
“…A new organization, the Coalition for Epidemic Preparedness Innovations (CEPI), was launched and has raised half a billion dollars to work on three [vaccines for emerging infections]. GlaxoSmithKline, one of only four large vaccinemakers in the world, has proposed devoting one of its idle manufacturing plants to be a facility dedicated to making vaccines for emerging infections, and is seeking CEPI funding. But other vaccinemakers have different ideas about how best to improve the response. And many of the people at the front of reinventing the way the world responds to emerging infections stress that the problem in need of fixing is much larger than simply manufacturing novel vaccines…” (Cohen, 4/14).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.